Ethic Inc. Invests $116,000 in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Ethic Inc. acquired a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 37,238 shares of the company’s stock, valued at approximately $116,000.

Several other institutional investors also recently modified their holdings of the company. Almanack Investment Partners LLC. increased its stake in shares of Ginkgo Bioworks by 22.3% during the 2nd quarter. Almanack Investment Partners LLC. now owns 17,850 shares of the company’s stock worth $42,000 after purchasing an additional 3,250 shares during the last quarter. Treasurer of the State of North Carolina boosted its holdings in shares of Ginkgo Bioworks by 1.3% during the 3rd quarter. Treasurer of the State of North Carolina now owns 351,677 shares of the company’s stock worth $1,097,000 after buying an additional 4,540 shares during the period. Formidable Asset Management LLC boosted its holdings in shares of Ginkgo Bioworks by 32.1% during the 2nd quarter. Formidable Asset Management LLC now owns 20,332 shares of the company’s stock worth $64,000 after buying an additional 4,946 shares during the period. Bradley Foster & Sargent Inc. CT boosted its holdings in shares of Ginkgo Bioworks by 7.3% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 74,390 shares of the company’s stock worth $177,000 after buying an additional 5,035 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in shares of Ginkgo Bioworks by 104.6% during the 3rd quarter. Van ECK Associates Corp now owns 12,740 shares of the company’s stock worth $39,000 after buying an additional 6,512 shares during the period. 61.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Jason R. Kelly sold 258,748 shares of the company’s stock in a transaction that occurred on Wednesday, January 25th. The shares were sold at an average price of $1.73, for a total transaction of $447,634.04. Following the completion of the sale, the insider now owns 14,947,040 shares of the company’s stock, valued at approximately $25,858,379.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Reshma P. Shetty sold 37,650 shares of the company’s stock in a transaction that occurred on Wednesday, February 22nd. The shares were sold at an average price of $1.65, for a total transaction of $62,122.50. Following the completion of the sale, the insider now owns 13,993,504 shares of the company’s stock, valued at approximately $23,089,281.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jason R. Kelly sold 258,748 shares of the company’s stock in a transaction that occurred on Wednesday, January 25th. The stock was sold at an average price of $1.73, for a total transaction of $447,634.04. Following the sale, the insider now directly owns 14,947,040 shares of the company’s stock, valued at approximately $25,858,379.20. The disclosure for this sale can be found here. Insiders sold 4,812,538 shares of company stock valued at $8,334,686 in the last quarter. Company insiders own 17.47% of the company’s stock.

Ginkgo Bioworks Trading Down 5.3 %

NYSE DNA opened at $1.25 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.71 and a quick ratio of 11.67. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $1.22 and a 12-month high of $4.91. The firm has a 50-day moving average price of $1.70 and a two-hundred day moving average price of $2.20.

Wall Street Analyst Weigh In

Several brokerages recently commented on DNA. Berenberg Bank began coverage on shares of Ginkgo Bioworks in a report on Monday, November 28th. They set a “buy” rating and a $6.00 target price for the company. BTIG Research reduced their target price on shares of Ginkgo Bioworks from $4.00 to $3.00 in a report on Sunday, March 5th. Finally, Raymond James reduced their target price on shares of Ginkgo Bioworks from $6.00 to $5.00 and set an “outperform” rating for the company in a report on Friday, March 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.39.

About Ginkgo Bioworks

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.